Amongst the identified NAMPT inhibitors, the prototypical compound FK866 (also known as (E)-Daporinad) [41], CHS-828 [42,43], and its prodrug GMX1777 [44] were evaluated in cancer patients in early-phase clinical trials. This evidence concerns the gene NAMPT and cancer.